Literature DB >> 25739575

NCI launches exceptional responders initiative: researchers will attempt to identify why some patients respond to treatment so much better than others.

Carrie Printz.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25739575     DOI: 10.1002/cncr.29311

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  6 in total

Review 1.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 2.  Future Clinical Trials: Genetically Driven Trials.

Authors:  Igor Astsaturov
Journal:  Surg Oncol Clin N Am       Date:  2017-08-18       Impact factor: 3.495

3.  No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Authors:  Zachary Veitch; Domen Ribnikar; Derek Tilley; Patricia A Tang; Karen King; Philippe L Bedard; Sasha Lupichuk; David W Cescon
Journal:  Br J Cancer       Date:  2021-12-20       Impact factor: 9.075

Review 4.  Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Authors:  Flurina A M Saner; Alan Herschtal; Brad H Nelson; Anna deFazio; Ellen L Goode; Susan J Ramus; Ahwan Pandey; Jessica A Beach; Sian Fereday; Andrew Berchuck; Stephanie Lheureux; Celeste Leigh Pearce; Paul D Pharoah; Malcolm C Pike; Dale W Garsed; David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

5.  OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine.

Authors:  John Orechia; Ameet Pathak; Yunling Shi; Aniket Nawani; Andrey Belozerov; Caitlin Fontes; Camille Lakhiani; Chetan Jawale; Chetansharan Patel; Daniel Quinn; Dmitry Botvinnik; Eddie Mei; Elizabeth Cotter; James Byleckie; Mollie Ullman-Cullere; Padam Chhetri; Poornima Chalasani; Purushotham Karnam; Ronald Beaudoin; Sandeep Sahu; Yelena Belozerova; Jomol P Mathew
Journal:  Appl Transl Genom       Date:  2015-09-14

6.  Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.

Authors:  T Vu; W Gonsalves; S Kumar; A Dispenzieri; M Q Lacy; F Buadi; M A Gertz; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-23       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.